Prothena Announces Proposed Secondary Offering of Ordinary Shares by Perrigo
DUBLIN, Ireland, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery,
development and commercialization of novel antibodies for the potential
treatment of diseases that involve protein misfolding and cell adhesion,
announced today the underwritten public offering of 2,767,177 ordinary shares of
Prothena by Elan Science One Limited (the "Selling Shareholder"), an indirect
wholly owned subsidiary of Perrigo Company plc ("Perrigo"). In addition, the
Selling Shareholder has granted the underwriters a 30-day option to purchase up
to an additional 415,076 ordinary shares.
All of the ordinary shares are being sold by the Selling Shareholder. If the
underwriters' option is exercised in full, the Selling Shareholder and Perrigo
will no longer own any ordinary shares of Prothena. Prothena will not receive
any of the proceeds from the offering, and the total number of Prothena ordinary
shares outstanding will not change as a result of the offering.
BofA Merrill Lynch and Citigroup are acting as joint book-running managers for
the offering. The offering is subject to market conditions, and there can be no
assurance as to whether or when the offering will be completed, or as to the
actual size of terms of the offering.
A registration statement on Form S-3 relating to the ordinary shares has been
filed with the Securities and Exchange Commission and declared effective. The
offering of these securities will be made only by means of a written prospectus
supplement and base prospectus forming part of the effective registration
statement relating to the ordinary shares. Copies of the prospectus for this
offering may be obtained, when available, by contacting BofA Merrill Lynch, 222
Broadway, New York, NY 10038, Attn: Prospectus Department, email:
email@example.com, or Citigroup, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at
1-800-831-9146 or email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or other jurisdiction.
CONTACT: Investors: Tran Nguyen, CFO
Media: Anita Kawatra
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Prothena Corporation via GlobeNewswire